Kasvu Therapeutics raises €30M Series A for depression drug

Helsinki’s Kasvu Therapeutics has raised a €30M Series A led by Hadean Ventures to take KTX-0141, a first-in-class TrkB potentiator for major depressive disorder, into clinical development from H2 2027.

I keep hearing that Europe cannot fund hard science at Series A. And then a three-year-old University of Helsinki spinout closes €30M to go after one of the hardest problems in medicine – depression – with a cap table that never leaves the Nordics.

A €30M round with an all-Nordic cap table

Kasvu Therapeutics announced the round on 24 September 2026. Specialist life sciences investor Hadean Ventures leads; Tesi (the Finnish state investment company), the Innovestor Life Science Fund, the Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments and Helsinki University Funds all participate, several of them returning from the seed. On top of the equity, the company counts strategic funding from Business Finland.

The money has one job: carry KTX-0141, the company’s lead candidate, through IND and CTA-enabling studies and into Phase 1/1b trials in major depressive disorder. Clinical development is expected to start in the second half of 2027, and the company says the first trials will already include an initial efficacy assessment with a control arm – unusually ambitious for a Phase 1 programme, and a signal of how much the team trusts its preclinical package.

Psychedelic plasticity, without the psychedelic

Kasvu spun out of the University of Helsinki in 2023, building on Professor Eero Castrén’s research into BDNF and TrkB signalling – the work that showed how antidepressants, and later psychedelics, promote neuroplasticity by acting on the TrkB receptor. CEO and co-founder Jami Mandelin leads the team alongside CMO Matti Karvonen and CBO Georgios Trichas.

KTX-0141 is a small-molecule TrkB positive allosteric modulator. In plain words: instead of flooding the brain with serotonin, or sending patients on a six-hour supervised trip, it amplifies the brain’s own BDNF signal – the growth factor behind neuroplasticity – while leaving 5-HT2A, the receptor responsible for hallucinations, untouched. Preclinical studies showed enhanced structural and functional neuroplasticity with no hallucinogenic activity in a standard animal model. “In just three years, we have advanced from a bold scientific hypothesis to a highly selective, first-in-class TrkB potentiator,” Mandelin said in the announcement, pointing at a “rapid-acting and long-lasting treatment with convenient at-home use”.

That last phrase is the business model. Psilocybin and esketamine therapies need clinics, supervision and hours of clinician time per dose. A pill that delivers the plasticity without the trip skips all of it.

A $15.4bn market growing at 3.8% – and why that is the point

The WHO counts about 280 million people living with depression worldwide. Grand View Research sizes the global anxiety disorders and depression treatment market at $15.4bn in 2024, reaching $19.3bn by 2030 at a 3.8% CAGR (Grand View Research, 2025). A growth rate that sleepy sounds like bad news – and it is precisely the story. The market runs on decades-old generic monoamines that cost cents and leave a large share of patients without remission. The value is not in the volume; it sits with the first genuinely new mechanisms in a generation, which is exactly where investors are placing their cheques.

Kasvu’s round also fits a European life sciences week that keeps surprising: Biolevate’s €30M Series A in Paris, Basecamp Research’s $140M Series C in London, and now Helsinki. Three cities, three mechanisms, one pattern – deep science raising real money at home.

What the Nordic capital stack signals

So who is actually around the table? A university’s own fund. A national drug discovery centre. The state investor. A specialist Nordic life sciences VC. Business Finland underneath as strategic support. This is the model Europe keeps saying it wants – patient public capital de-risking the science, specialists leading, the university keeping skin in the game – and in Helsinki it is not a policy paper, it is simply operating.

What we are seeing is European neuroscience moving out of the psychedelics hype cycle and into its chemistry: keep the mechanism, drop the trip, keep the IP at home. The thing to watch is 2027-28 – whether that first efficacy readout pulls US crossover money into the Series B, or whether the Nordics hold that round too.

Every round in this series lands in our fundraising data. Depression has waited three decades for a truly new mechanism – Helsinki just put €30M behind one. Let’s watch that readout closely!